Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Attack -- A Complete Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Sonki who wrote (19104)	1/29/1999 7:53:00 PM
From: Judy	Read Replies (1) \| Respond to of 42787

This is my vision for the drug sector ... Analysts have the drug sector pegged as trading at historically high PE's only because it is relative to trailing earnings and some companies will have drug patents expiring within the next year. However specific companies with strong pipelines will be going forward with FDA submittals in '99; analysts will revamp their earnings estimates based on future revenue potential of what is coming out of the pipelines. Hence the drug sector will once again move on momentum of future growth. And if my market sense is correct, the market will be entering a corrective phase as new drugs in the pipeline is being promoted, then BAMM, defensive stocks will future growth potential will be in vogue. sonki, the tech rally may be heading for some type of blowoff. DELL is not close to blowing off yet ... after all, it has rested for two quarters in transition.